Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

计划入组 150 人 · 首次发布于 2026 年 3 月 23 日

A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z

计划入组 38 人 · 首次发布于 2015 年 5 月 22 日

202091 (EBOLA Z CHAD3-005)

计划入组 3,000 人

Z-338 Z-338

Z-11410

Z-1054

E-Z-EM, Inc.

United States

Alam, Dr Z Yasim

Canada

BIOVICO SP Z O O

Poland

Dyne Therapeutics Reports Sustained One-Year Functional Improvements with Zeleciment Basivarsen in Myotonic Dystrophy Type 1

Novartis' Del-desiran Misses Primary Endpoint in Phase 3 HARBOR, Rattling DMPK-Targeting Field

UnitedHealthcare to Require DEX Z-Codes for Molecular Diagnostic Tests in Phase 3